Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 October 2024 - 6:01AM
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint
preservation company in early intervention orthopedics, today
announced that on October 1, 2024, Anika granted non-statutory
stock options (“Options”) covering an aggregate of 6,350 shares of
common stock at a per share exercise price of $24.27, which equaled
the closing price of common stock on the Nasdaq Global Select
Market (“Closing Price”) on the grant date, to one newly hired
non-executive employee. The grant was made pursuant to the Anika
Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved
by the compensation committee of the board of directors pursuant to
a delegation of authority by the board of directors, and, in
accordance with Nasdaq Listing Rule 5635(c)(4), was made as a
material inducement to the grantee’s acceptance of employment with
Anika as a component of the grantee’s employment compensation.
Of the shares covered by the Options, one-third
will vest on each of the first three anniversaries of the grant
date, in each case for so long as the grantee provides continuous
service to Anika through the relevant vesting date.
Unless earlier terminated in accordance with their
terms, the Options will expire on the tenth anniversary of the
grant date and are otherwise subject to the terms and conditions of
the equity award agreement approved by Anika. The Options were
granted pursuant to the Anika Therapeutics, Inc. 2021 Inducement
Plan, as amended, which was not subject to stockholder
approval.
About Anika Anika Therapeutics,
Inc. (NASDAQ: ANIK), is a global joint preservation company that
creates and delivers meaningful advancements in early intervention
orthopedic care. Leveraging our core expertise in hyaluronic acid
and implant solutions, we partner with clinicians to provide
minimally invasive products that restore active living for people
around the world. Our focus is on high opportunity spaces within
orthopedics, including Osteoarthritis Pain Management, Regenerative
Solutions, Sports Medicine and Arthrosurface Joint Solutions, and
our products are efficiently delivered in key sites of care,
including ambulatory surgery centers. Anika’s global operations are
headquartered outside of Boston, Massachusetts. For more
information about Anika, please visit www.anika.com.
ANIKA, ANIKA THERAPEUTICS and the Anika logo are
registered trademarks of Anika Therapeutics, Inc.
For Investor Inquiries:Anika
Therapeutics, Inc.Matt Hall, 781-457-9554Director, Corporate
Development and Investor Relationsinvestorrelations@anika.com
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Oct 2024 to Nov 2024
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Nov 2023 to Nov 2024